- Email: [email protected]
Effects of cosmeceuticals containing matrikines post–fractional resurfacing with radiofrequency and twice daily for 12 weeks
2452
3729
Effect of midfacial augmentation with nonanimal stabilized hyaluronic acid on the nasolabial fold and overall aesthetic appearance Brian Biesman, MD, Clinical Assistant Professor, Ophthalmology, Dermatology, Otolaryngology Vanderbilt University, Nashville, TN, United States; Whitney Bowe, MD, Advanced Dermatology PC, Briarcliff Manor, NY, United States
Effects of oral glutathione on skin appearances: A randomized placebocontrolled study Sinee Weschawalit, MD, Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Pravit Asawanonda, MD, Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Introduction: Nonanimal stabilized hyaluronic acid (Perlane, Galderma, SA) was FDA approved in 2007 for the treatment of facial wrinkles and folds. Off-label use led to the observation that injection of Perlane in the midface improved both global aesthetic appearance and reduced the depth of nasolabial folds. A proof-of-concept trial was undertaken to explore this clinical observation further. Methods: 20 subjects with moderate midfacial volume loss and prominence of nasolabial folds underwent injection of the midface with Perlane between May and July, 2009. The average volume administered was 3.68 6 0.55 ml. Assessments were performed by the injecting physician and subject self-assessment for 6 months following treatment. Results: 17 of 20 subjects completed all study visits. At the 6-month follow-up visit, 16 of 17 subjects were found to have clinically significant improvement of the midface and 14 of 17 subjects were found to have clinically significant improvement of the nasolabial folds. No serious adverse events occurred. Conclusion: In this early stage, proof-of-concept trial, the majority of patients treated demonstrated clinically significant, aesthetically pleasing improvement 6 months after injection of Perlane in the midface. This was an investigator-initiated study funded by Medicis.
Background: Glutathione has been shown to lighten the skin when administered at 500 mg per day in an oral form for 4 weeks. Objective: To evaluate skin lightening and antiaging efficacies of oral glutathione, 250 mg per day, in its reduced and oxidized forms compared to placebo. Materials and methods: This was a randomized, placebo-controlled, double blind, parallel, three-arm study. Sixty healthy females, aged between 20-50 years were enrolled and randomized in to 3 groups; 1:1:1 ratio. Subjects received reduced glutathione (GSH) 250 mg/day, oxidized glutathione (GSSG) 250 mg/day or placebo for 12 weeks. Melanin index and other skin properties, i.e. UV spots, transepidermal water loss, water contents, elasticity and wrinkle were measured every 4 weeks. Results: Fifty-seven subjects completed the study. Both reduced and oxidized forms of glutathione effected in decreasing melanin indices, which reached statistically significant levels at some sites and time points. Reduced form of glutathione improved wrinkles at some anatomic location. And also both forms of glutathione showed trends in increased skin elasticity at various site, both sun-exposed and sunprotected skin. Conclusion: Oral glutathione, 250 mg per day, in both reduced and oxidized forms had beneficial effects as a skin lightening and possibly an antiaging agent. GSSG (250 mg/day), GSH (250 mg/day), dibasic calcium phosphate as placebo in identical capsules and packages were provided by Kyowa Hakko Bio Co., LTD (Tokyo, Japan).
3849 Enhanced efficacy of combining a topical antioxidants regimen with a home use nonablative fractional diode laser in treatment of photodamaged facial skin Roy Geronemus, MD, Laser & Skin Surgery Center of New York, New York, NY, United States; Ana Du, L’Oreal Research & Innovation, Clark, NJ, United States; Margarita Yatskayer, MS, L’Oreal Research & Innovation, Clark, NJ, United States; Stephen Lynch, PhD, L’Oreal Research & Innovation, Clark, NJ, United States; Yevgeniy Krol, Skinceuticals Inc, New York, NY, United States; Christian Oresajo, PhD, L’Oreal Research & Innovation, Clark, NJ, United States Background and objective: Topical products and nonablative fractional laser devices are commonly used to address photodamaged skin. This single center, 24-week, split face, evaluator-blinded, randomized clinical study was conducted to evaluate the enhanced efficacy and tolerance of a topical antioxidant regimen: a serum containing 15% pure l-ascorbic acid, 1% alpha tocopherol, and 0.5% ferulic acid, combined with a concentrate containing 1% Resveratrol, 1% alpha tocopherol, and 0.5% Baicalin (Skinceuticals, NY Inc) in conjunction with a home use nonablative laser device.
3821 Effects of cosmeceuticals containing matrikines postefractional resurfacing with radiofrequency and twice daily for 12 weeks Natalie Curcio, MD, MPH, Nashville, TN, United States We conducted a twelve-week case series of ten patients to evaluate a new cosmeceutical line using matrikines, growth-factor like products derived from the ECM, immediately postefractional laser resurfacing with radiofrequency on the face and neck and for the following twelve weeks. Using high-resolution clinical photos and VISIA image analysis, we evaluated fine lines and wrinkles, texture, pores, and laxity. Global Aesthetic Improvement Scales (GAIS) were evaluated by a practitioner comparing baseline and follow-up photos. Using a Likert scale, fine lines and wrinkles, texture, laxity, and postprocedural redness, swelling, discomfort, and speed of healing were evaluated at 12 weeks via a patient self-assessment questionnaire. NEOCUTIS Products (Micro-Night and Micro-Eyes) were supplied to patients for duration of study.
AB16
J AM ACAD DERMATOL
Method: 43 females, ages 40-65, Fitzpatrick skin types I-III, with moderate dyschromia, erythema, and wrinkles in the peri-orbital and perioral areas of the face were enrolled for the 24-week study. Each subject was provided with use instruction for the 1440 nm, 5-12 mJ/pulse, non-ablative fractional diode laser (Tria Beauty, Inc, CA) for full face home use for the first 12 weeks of the study along with sunscreen and moisturizer. Each subject was also told which side of the face (left or right) to apply the antioxidant regimen, based on a computer generated randomization list. After 12 weeks, the subjects were instructed to continue the use of sunscreen and moisturizer only for the next 2 weeks. Starting from week 14, the remaining subjects (n ¼ 16) used the moisturizer and sunscreen on the entire face and the antioxidant regimen on the same facial half as the first 12 weeks. Clinical efficacy, tolerability assessments and digital images were included at baseline, weeks 2, 4, 8, 12, 14, 16, and 24, including tolerability after single application and day 3. Self-assessment questionnaires were completed after single application, weeks 2, 4, 8, 12, 14, 16, and 24. Results: Results indicated that at weeks 4, 8, and 12, statistically significant improvements were observed in almost all evaluated parameters for both treatments compared to baseline. At week 12, the side treated with laser device and antioxidant regimen demonstrated greater improvement in evaluated parameters such as hyperpigmentation, skin texture/smoothness, and skin tone evenness. This clearly demonstrates that the addition of the antioxidant regimen enhanced the clinical benefits of the laser device. At the final week 24 time point, use of the antioxidant test products provided greater improvement than support materials alone in Supported 100% by L’Oreal.
MAY 2016
3729
Effect of midfacial augmentation with nonanimal stabilized hyaluronic acid on the nasolabial fold and overall aesthetic appearance Brian Biesman, MD, Clinical Assistant Professor, Ophthalmology, Dermatology, Otolaryngology Vanderbilt University, Nashville, TN, United States; Whitney Bowe, MD, Advanced Dermatology PC, Briarcliff Manor, NY, United States
Effects of oral glutathione on skin appearances: A randomized placebocontrolled study Sinee Weschawalit, MD, Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Pravit Asawanonda, MD, Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Introduction: Nonanimal stabilized hyaluronic acid (Perlane, Galderma, SA) was FDA approved in 2007 for the treatment of facial wrinkles and folds. Off-label use led to the observation that injection of Perlane in the midface improved both global aesthetic appearance and reduced the depth of nasolabial folds. A proof-of-concept trial was undertaken to explore this clinical observation further. Methods: 20 subjects with moderate midfacial volume loss and prominence of nasolabial folds underwent injection of the midface with Perlane between May and July, 2009. The average volume administered was 3.68 6 0.55 ml. Assessments were performed by the injecting physician and subject self-assessment for 6 months following treatment. Results: 17 of 20 subjects completed all study visits. At the 6-month follow-up visit, 16 of 17 subjects were found to have clinically significant improvement of the midface and 14 of 17 subjects were found to have clinically significant improvement of the nasolabial folds. No serious adverse events occurred. Conclusion: In this early stage, proof-of-concept trial, the majority of patients treated demonstrated clinically significant, aesthetically pleasing improvement 6 months after injection of Perlane in the midface. This was an investigator-initiated study funded by Medicis.
Background: Glutathione has been shown to lighten the skin when administered at 500 mg per day in an oral form for 4 weeks. Objective: To evaluate skin lightening and antiaging efficacies of oral glutathione, 250 mg per day, in its reduced and oxidized forms compared to placebo. Materials and methods: This was a randomized, placebo-controlled, double blind, parallel, three-arm study. Sixty healthy females, aged between 20-50 years were enrolled and randomized in to 3 groups; 1:1:1 ratio. Subjects received reduced glutathione (GSH) 250 mg/day, oxidized glutathione (GSSG) 250 mg/day or placebo for 12 weeks. Melanin index and other skin properties, i.e. UV spots, transepidermal water loss, water contents, elasticity and wrinkle were measured every 4 weeks. Results: Fifty-seven subjects completed the study. Both reduced and oxidized forms of glutathione effected in decreasing melanin indices, which reached statistically significant levels at some sites and time points. Reduced form of glutathione improved wrinkles at some anatomic location. And also both forms of glutathione showed trends in increased skin elasticity at various site, both sun-exposed and sunprotected skin. Conclusion: Oral glutathione, 250 mg per day, in both reduced and oxidized forms had beneficial effects as a skin lightening and possibly an antiaging agent. GSSG (250 mg/day), GSH (250 mg/day), dibasic calcium phosphate as placebo in identical capsules and packages were provided by Kyowa Hakko Bio Co., LTD (Tokyo, Japan).
3849 Enhanced efficacy of combining a topical antioxidants regimen with a home use nonablative fractional diode laser in treatment of photodamaged facial skin Roy Geronemus, MD, Laser & Skin Surgery Center of New York, New York, NY, United States; Ana Du, L’Oreal Research & Innovation, Clark, NJ, United States; Margarita Yatskayer, MS, L’Oreal Research & Innovation, Clark, NJ, United States; Stephen Lynch, PhD, L’Oreal Research & Innovation, Clark, NJ, United States; Yevgeniy Krol, Skinceuticals Inc, New York, NY, United States; Christian Oresajo, PhD, L’Oreal Research & Innovation, Clark, NJ, United States Background and objective: Topical products and nonablative fractional laser devices are commonly used to address photodamaged skin. This single center, 24-week, split face, evaluator-blinded, randomized clinical study was conducted to evaluate the enhanced efficacy and tolerance of a topical antioxidant regimen: a serum containing 15% pure l-ascorbic acid, 1% alpha tocopherol, and 0.5% ferulic acid, combined with a concentrate containing 1% Resveratrol, 1% alpha tocopherol, and 0.5% Baicalin (Skinceuticals, NY Inc) in conjunction with a home use nonablative laser device.
3821 Effects of cosmeceuticals containing matrikines postefractional resurfacing with radiofrequency and twice daily for 12 weeks Natalie Curcio, MD, MPH, Nashville, TN, United States We conducted a twelve-week case series of ten patients to evaluate a new cosmeceutical line using matrikines, growth-factor like products derived from the ECM, immediately postefractional laser resurfacing with radiofrequency on the face and neck and for the following twelve weeks. Using high-resolution clinical photos and VISIA image analysis, we evaluated fine lines and wrinkles, texture, pores, and laxity. Global Aesthetic Improvement Scales (GAIS) were evaluated by a practitioner comparing baseline and follow-up photos. Using a Likert scale, fine lines and wrinkles, texture, laxity, and postprocedural redness, swelling, discomfort, and speed of healing were evaluated at 12 weeks via a patient self-assessment questionnaire. NEOCUTIS Products (Micro-Night and Micro-Eyes) were supplied to patients for duration of study.
AB16
J AM ACAD DERMATOL
Method: 43 females, ages 40-65, Fitzpatrick skin types I-III, with moderate dyschromia, erythema, and wrinkles in the peri-orbital and perioral areas of the face were enrolled for the 24-week study. Each subject was provided with use instruction for the 1440 nm, 5-12 mJ/pulse, non-ablative fractional diode laser (Tria Beauty, Inc, CA) for full face home use for the first 12 weeks of the study along with sunscreen and moisturizer. Each subject was also told which side of the face (left or right) to apply the antioxidant regimen, based on a computer generated randomization list. After 12 weeks, the subjects were instructed to continue the use of sunscreen and moisturizer only for the next 2 weeks. Starting from week 14, the remaining subjects (n ¼ 16) used the moisturizer and sunscreen on the entire face and the antioxidant regimen on the same facial half as the first 12 weeks. Clinical efficacy, tolerability assessments and digital images were included at baseline, weeks 2, 4, 8, 12, 14, 16, and 24, including tolerability after single application and day 3. Self-assessment questionnaires were completed after single application, weeks 2, 4, 8, 12, 14, 16, and 24. Results: Results indicated that at weeks 4, 8, and 12, statistically significant improvements were observed in almost all evaluated parameters for both treatments compared to baseline. At week 12, the side treated with laser device and antioxidant regimen demonstrated greater improvement in evaluated parameters such as hyperpigmentation, skin texture/smoothness, and skin tone evenness. This clearly demonstrates that the addition of the antioxidant regimen enhanced the clinical benefits of the laser device. At the final week 24 time point, use of the antioxidant test products provided greater improvement than support materials alone in Supported 100% by L’Oreal.
MAY 2016